Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Congestive cardiomyopathy? 204 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 204 reports of Congestive cardiomyopathy have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.3% of all adverse event reports for DOXORUBICIN.

204
Reports of Congestive cardiomyopathy with DOXORUBICIN
0.3%
of all DOXORUBICIN reports
33
Deaths
131
Hospitalizations

How Dangerous Is Congestive cardiomyopathy From DOXORUBICIN?

Of the 204 reports, 33 (16.2%) resulted in death, 131 (64.2%) required hospitalization, and 46 (22.5%) were considered life-threatening.

Is Congestive cardiomyopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 204 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Congestive cardiomyopathy?

SACUBITRIL\VALSARTAN (218) CYCLOPHOSPHAMIDE (180) ROSIGLITAZONE (125) CLOZAPINE (120) QUETIAPINE (107) EPIRUBICIN (95) BISOPROLOL (92) FUROSEMIDE (91) RITUXIMAB (90) VINCRISTINE (87)

Which DOXORUBICIN Alternatives Have Lower Congestive cardiomyopathy Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Congestive cardiomyopathy Reports All Drugs Causing Congestive cardiomyopathy DOXORUBICIN Demographics